TG Therapeutics, Inc.
General ticker "TGTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.1B (TTM average)
TG Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -18.5%.
Estimated limits based on current volatility of 4.7%: low 28.92$, high 31.75$
Factors to consider:
- Total employees count: 338 as of 2024
- US accounted for 94.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Clinical trial success, Labor/talent shortage/retention, Intellectual property risks, Expansion risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [23.99$, 56.52$]
- 2025-12-31 to 2026-12-31 estimated range: [20.51$, 48.57$]
Financial Metrics affecting the TGTX estimates:
- Positive: with PPE of 227.2 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -0.88 <= 0.04
- Positive: 7.54 < Operating profit margin, % of 12.74
- Negative: negative Industry operating cash flow (median)
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 3.89
- Positive: Investing cash flow per share per price, % of -0.02 > -0.62
- Positive: 19.35 < Shareholder equity ratio, % of 38.49 <= 42.53
- Negative: Inventory ratio change, % of 8.62 > 0.82
- Negative: -0.18 < Industry inventory ratio change (median), % of 0
- Negative: Industry earnings per price (median), % of -16.21 <= 0
Short-term TGTX quotes
Long-term TGTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2.79MM | $233.66MM | $329.00MM |
| Operating Expenses | $221.10MM | $213.03MM | $287.07MM |
| Operating Income | $-218.32MM | $20.63MM | $41.93MM |
| Non-Operating Income | $-5.50MM | $-7.57MM | $-16.34MM |
| Interest Expense | $10.19MM | $12.62MM | $24.03MM |
| R&D Expense | $125.35MM | $76.19MM | $94.29MM |
| Income(Loss) | $-223.81MM | $13.06MM | $25.59MM |
| Taxes | $0.00MM | $0.39MM | $2.21MM |
| Profit(Loss)* | $-198.34MM | $12.67MM | $23.38MM |
| Stockholders Equity | $58.59MM | $160.50MM | $222.36MM |
| Inventory | $0.00MM | $39.82MM | $110.46MM |
| Assets | $193.57MM | $329.59MM | $577.69MM |
| Operating Cash Flow | $-176.17MM | $-31.41MM | $-40.52MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.04MM |
| Investing Cash Flow | $-20.01MM | $-50.65MM | $-1.04MM |
| Financing Cash Flow | $-0.39MM | $72.70MM | $128.53MM |
| Earnings Per Share** | $-1.46 | $0.09 | $0.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.